source
- Medicare uptake of newly approved Alzheimer’s drugs Leqembi and Kisunla falls short of expectationsMedicare is seeing much lower use of the two Alzheimer’s treatments that received FDA approval earlier this year. The drugs, Leqembi and Kisunla, were expected to generate notable spending for Med…
- European regulators approve Fractyl Health's first GLP-1 gene therapy clinical trialEuropean regulators have given the green light for Fractyl Health, a biotech near Boston, to begin its first human study of a GLP-1 gene therapy. The therapy aims to provide a one-time treatment t…